{"nctId":"NCT03408730","briefTitle":"Lot-to-lot Consistency of Sci-B-Vac™ in Adults","startDateStruct":{"date":"2017-12-14","type":"ACTUAL"},"conditions":["Hepatitis B Vaccines"],"count":2838,"armGroups":[{"label":"Sci-B-Vac Lot A Hep B Vaccination","type":"EXPERIMENTAL","interventionNames":["Biological: Hepatitis B Vaccination"]},{"label":"Sci-B-Vac Lot B Hep B Vaccination","type":"EXPERIMENTAL","interventionNames":["Biological: Hepatitis B Vaccination"]},{"label":"Sci-B-Vac Lot C Hep B Vaccination","type":"EXPERIMENTAL","interventionNames":["Biological: Hepatitis B Vaccination"]},{"label":"Comparator: ENGERIX-B Hep B Vaccination","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Hepatitis B Vaccination"]}],"interventions":[{"name":"Hepatitis B Vaccination","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Any gender\n* Age 18-45 years\n* Healthy, as determined by a physical examination and values of laboratory tests\n* If female, either is not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), is of childbearing potential and must agree to use an adequate birth control method\n* Able and willing to give informed consent\n\nExclusion Criteria:\n\n* Previous vaccination with any Hep B vaccine (HBV) (licensed or experimental)\n* Treatment by immunosuppressant within 30 days of enrollment\n* History of immunological function impairment\n* Pregnancy or breastfeeding\n* Immunization with attenuated vaccines (e.g. MMR) within 4 weeks prior to enrollment\n* Immunization with inactivated vaccines (e.g. influenza) within 2 week prior to enrolment\n* Has received blood products or immunoglobulin within 90 days of enrollment or is likely to require blood products during the study period\n* Subject in another clinical trial with an investigational drug or a biologic within 30 days of enrollment\n* Has received granulocyte-macrophage colony stimulating factor (G/GM-CSF) or erythropoietin (EPO) within 30 days of enrollment or likely to require GM-CSF or erythropoietin during the study period\n* Any history of cancer requiring chemotherapy or radiation within 5 years of randomization or current disease.\n* Any skin abnormality or tattoo that would limit post-vaccination injection site assessment\n* History of allergic reactions or anaphylactic reaction to any vaccine component\n* Unwilling, or unable in the opinion of the investigator, to comply with study requirements\n* Immediate family members of study center staff\n* Current or past hepatitis B infection or prior vaccination as evidenced by HBV markers\n* Known hepatitis C infection or positive Hepatitis C serology at screening, unless treated and cured\n* Known human immunodeficiency virus (HIV) infection or positive HIV serology at screening\n* Renal impairment with Glomerular Filtration Rate (GFR) \\<90 mL/min/ 1.73 m2 at screening\n* BMI ≥ 35\n* Uncontrolled hypertension\n* Diagnosis of Type 1 or Type 2 diabetes or HbA1C ≥ 6.5% at screening\n* Any laboratory test abnormality that would be considered of Grade 1 severity or above as per FDA guidelines for grading clinical laboratory abnormalities and is considered as clinically significant by the investigator.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Concentration (GMC) of Anti-HBs at Day 196 for Lot-to-Lot Consistency (Per Protocol Set 1)","description":"To demonstrate the manufacturing equivalence, in terms of immunogenicity, as measured by GMC of antibodies, of 3 independent consecutive lots of the Sci-B-Vac® 4 weeks after the third vaccination. Lot-to-lot manufacturing consistency of Sci-B-Vac® is demonstrated if the 95% CIs of the adjusted anti-HBs GMC ratios between lots are within the pre-specified range of \\[0.67, 1.5\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5883.93","spread":"5.423"},{"groupId":"OG001","value":"4824.06","spread":"6.293"},{"groupId":"OG002","value":"5505.98","spread":"5.975"}]}]}]},{"type":"SECONDARY","title":"Seroprotection Rate (SPR) of Anti-HBs at Day 196 for Sci-B-Vac® Compared to Day 196 for Engerix-B® (Per Protocol Set 2)","description":"The difference in proportions \\[SPR(Sci-B-Vac®)-SPR(Engerix-B®)\\] and two-sided 95% CIs were summarized. If the lower bound of the 95% CI was \\> 5%, Sci-B-Vac® was to be declared non-inferior to Engerix-B®","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"561","spread":null},{"groupId":"OG001","value":"1740","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs)","description":"Analysis of local and systemic solicited adverse events with an interval of onset of Day 1 to Day 7 after any vaccination with either Sci-B-Vac® or Engerix-B®, in adults ≥18 years old.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"384","spread":null},{"groupId":"OG001","value":"527","spread":null},{"groupId":"OG002","value":"536","spread":null},{"groupId":"OG003","value":"542","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"391","spread":null},{"groupId":"OG001","value":"519","spread":null},{"groupId":"OG002","value":"535","spread":null},{"groupId":"OG003","value":"541","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"105","spread":null},{"groupId":"OG003","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"20","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"15","spread":null},{"groupId":"OG003","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"85","spread":null},{"groupId":"OG002","value":"87","spread":null},{"groupId":"OG003","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"94","spread":null},{"groupId":"OG002","value":"87","spread":null},{"groupId":"OG003","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"268","spread":null},{"groupId":"OG001","value":"255","spread":null},{"groupId":"OG002","value":"275","spread":null},{"groupId":"OG003","value":"281","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"284","spread":null},{"groupId":"OG001","value":"266","spread":null},{"groupId":"OG002","value":"296","spread":null},{"groupId":"OG003","value":"290","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":null},{"groupId":"OG001","value":"289","spread":null},{"groupId":"OG002","value":"316","spread":null},{"groupId":"OG003","value":"337","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":712},"commonTop":["Headache","Upper respiratory tract infection","Nasopharyngitis","Dysmenorrhoea","Fatigue"]}}}